Loading
Sentiment · FY2026 Q1
What companies say about each other on earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“So we do think it will take share from Botox.”
Medtronic expects its AltaViva tibial neurostimulation to take incontinence share from Botox (AbbVie).
“we're not going into indications where we have to go up against typically an AbbVie or a Sanofi or people like that.”
Biogen positions its immunology pipeline to avoid head-to-head competition with large players like AbbVie.
“the #1 selling adalimumab product is still HUMIRA and not AMJEVITA”
An analyst notes AbbVie's HUMIRA remains the top-selling adalimumab despite Amgen's AMJEVITA biosimilar, implying the originator has retained share against biosimilar competition.
“Examples include AbbVie's acquisition of a company called Capstone an early clinical stage company developing novel mRNA therapies for autoimmune diseases such as severe lupus, signaling that pharma is ready and willing to buy cutting-edge science.”
ARE cites AbbVie's acquisition of clinical-stage biotech Capstone as evidence that large pharma remains willing to pay up for early-stage science, a tailwind for ARE's life-science tenant base and future leasing demand.
“We're not, for example, with povorcitinib, copying all the indications for RINVOQ.”
Management contrasts its selective indication strategy for povorcitinib with AbbVie's broader RINVOQ label, positioning against a key JAK-inhibitor competitor.
“what's the strategy to build this market where AbbVie was unable to with annuity”
Analyst frames AbbVie as having failed to build the presbyopia eye-drop market (with Vuity), setting up Viatris's competing MR-141; a negative read-through for AbbVie's effort in the category.
“similar to HUMIRA's erosion curve, which is still our proxy”
J&J models STELARA's biosimilar-driven revenue erosion on the historical erosion curve of AbbVie's HUMIRA following its own biosimilar entry, using it as the benchmark proxy for forecasting.
“The challenge with the data that has been reported in the past with Humira and when you discuss this between physicians is that, while the response rate that has been reported was high and which has not been replicated since the original study, the drug failure on Humira is relatively fast.”
Incyte's CEO framed AbbVie's Humira as having disappointing real-world durability in hidradenitis suppurativa, positioning Incyte's povorcitinib as a differentiated alternative in that market.
“continue to partner with Gideon Richter and there's even a more D3 leaning asset that is within preclinical tox”
AbbVie references an ongoing psychiatry partnership with Gedeon Richter, including a more D3-leaning preclinical asset behind its 932/Vraylar franchise.
“in Pfizer yesterday, talked about that they are generating about 83% share in the new prescribers for in the migraine market.”
An analyst cites Pfizer's claimed 83% new-prescriber share in migraine; AbbVie disputes the framing given its larger combined Qlipta/Ubrelvy revenue, a competitive read-through in oral CGRP migraine.
“It sounds like you haven't really seen any change in new start share here with the Tremfya entry.”
An analyst probes competitive pressure from J&J's Tremfya on AbbVie's SKYRIZI in IBD; management says SKYRIZI new-start share remains stable, a read-through on J&J's IL-23 competitive traction.
“that just basically with the availability of drugs like Dupixent and Rinvoq, that may be in the high single-digit biopenetration for moderate to severe.”
AbbVie cites Dupixent alongside Rinvoq in the underpenetrated atopic dermatitis market, a competitive-landscape read-through.
“So you do have Amylin in this space now with Gubra.”
Analyst notes AbbVie's amylin obesity asset partnered from Gubra, a read-through on AbbVie's obesity/metabolic entry.
“On the oral side, the Nimble acquisition, these are macrocyclic molecules, the ones that we're focusing on, the attempt there is to make them as potent as possible and to extend the half-life.”
AbbVie's Nimble acquisition brings macrocyclic oral molecules (oral IL-23, TL1A) to its immunology pipeline.
“And our Gilgamesh and Gedeon Richter deals give us more depth in mood disorders.”
AbbVie's licensing deal with Gedeon Richter adds depth in mood disorders to its neuroscience pipeline.
“as well as the recent BD transactions for trispecific antibodies from Simcere and IGI.”
AbbVie licensed trispecific antibodies from Simcere (and IGI), expanding its oncology pipeline.
“primarily reflecting upfront charges for the acquisition of Capstan Therapeutics and our license agreement with IGI.”
AbbVie entered a license agreement with IGI, contributing upfront acquired IPR&D charges in the quarter.
“And closing the acquisition of CapstanTherapeutics, further strengthening our immunology pipeline with an in vivo CAR-T platform.”
AbbVie closed the acquisition of Capstan Therapeutics, adding an in vivo CAR-T platform to its immunology pipeline.
“Our recent deal activity includes announcing the acquisition of Gilgamesh's bretisilocin, expanding our psychiatry pipeline with a next-generation psychedelic currently in Phase II development for MDD.”
AbbVie acquired bretisilocin from Gilgamesh to expand its psychiatry pipeline with a next-gen psychedelic for major depressive disorder.
“we talk to Cigna all the time. Our account teams talk.”
AbbVie addresses Cigna's newly discussed PBM model, noting ongoing dialogue; a read-through on Cigna's evolving pharmacy-benefit approach.
AbbVie capped a strong fiscal year with record full-year revenue of $61.2 billion, beating guidance by over $2 billion, as Skyrizi and Rinvoq delivered $25.9 billion in combined revenue representing an $8 billion year-over-year increase. Revenue grew 10% in Q4 with adjusted EPS of $2.71, and management introduced 2026 guidance calling for approximately $67 billion in revenue with continued growth across the immunology portfolio. Humira erosion showed signs of moderating but was expected to continue into 2026.
Innovation & R&D | Competitive Dynamics | Revenue Growth | Demand | Regulation Policy | Pricing | M&A | Product Launch | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 3 | 3 | 5 | 7 | 2 | 4 | 2 | 2 |
| 2025Q1 | 4 | 4 | 4 | 1 | 5 | 2 | 1 | 1 |
| 2025Q2 | 3 | 4 | 4 | 4 | 1 | 1 | 2 | 2 |
| 2025Q3 | 5 | 4 | 3 | 2 | 4 | 2 | 1 | 2 |
| 2025Q4 | 7 | 5 | 1 | 1 | 2 | 1 | 1 | 2 |
| 2026Q1 | 7 | 5 | 2 | 2 | 3 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Innovation & R&D | 3 | 4 | 3 | 5 | 7 | 7 |
| Competitive Dynamics | 3 | 4 | 4 | 4 | 5 | 5 |
| Revenue Growth | 5 | 4 | 4 | 3 | 1 | 2 |
| Demand | 7 | 1 | 4 | 2 | 1 | 2 |
| Regulation Policy | 2 | 5 | 1 | 4 | 2 | |
| Pricing | 4 | 2 | 1 | 2 | 1 | |
| M&A | 2 | 1 | 2 | 1 | 1 | 3 |
| Product Launch | 2 | 1 | 2 | 2 | 2 | 1 |
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Chris Schott | JPMorgan | 9 (0%) |
| Steve Scala | TD Cowen | 8 (63%) |
| Dave Risinger | Leerink Partners |
| Terence Flynn | Morgan Stanley | 6 (17%) |
| Vamil Divan | Guggenheim | 6 (17%) |
| Mohit Bansal | Wells Fargo | 6 (0%) |
| Asad Haider | Goldman Sachs | 5 (20%) |
| Geoff Meacham | Citigroup | 4 (0%) |
| Dave Amsellem | Piper Sandler | 3 (0%) |
| Tim Anderson | Bank of America | 3 (67%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| JPMorgan | 1 | 9 (0%) |
| TD Cowen | 1 | 8 (63%) |
| Leerink Partners | 1 | 7 (0%) |
| Wells Fargo | 1 | 6 (0%) |
| Morgan Stanley | 1 | 6 (17%) |
| Guggenheim | 1 | 6 (17%) |
| Goldman Sachs | 2 | 6 (17%) |
| Citigroup | 1 | 4 (0%) |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
ABBV AbbVie | 9 | +12.4% | |
| AMGN Amgen Inc. | 8 | +5.8% | |
| BIIB Biogen | 4 | +1.9% | |
| BMY Bristol Myers Squibb | 4 | +2.6% | |
| GILD Gilead Sciences | 8 | +4.4% | |
| JNJ Johnson & Johnson | 7 | +10.1% | |
| LLY Lilly (Eli) | 10 | +55.5% | |
| MRK Merck & Co., Inc. | 7 | +4.3% | |
| PFE Pfizer | 5 | +5.4% |